Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$3.77 - $5.24 $64,953 - $90,279
-17,229 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$4.86 - $13.07 $218 - $588
45 Added 0.26%
17,229 $86,000
Q4 2020

Feb 12, 2021

BUY
$9.48 - $12.84 $767 - $1,040
81 Added 0.47%
17,184 $217,000
Q3 2020

Nov 04, 2020

SELL
$8.67 - $10.82 $3,372 - $4,208
-389 Reduced 2.22%
17,103 $168,000
Q2 2020

Aug 12, 2020

BUY
$7.8 - $11.52 $12,807 - $18,915
1,642 Added 10.36%
17,492 $174,000
Q1 2020

May 04, 2020

BUY
$5.98 - $13.09 $14,112 - $30,892
2,360 Added 17.49%
15,850 $140,000
Q4 2019

Feb 05, 2020

SELL
$5.71 - $9.22 $645 - $1,041
-113 Reduced 0.83%
13,490 $124,000
Q3 2019

Nov 08, 2019

SELL
$5.88 - $12.35 $552 - $1,160
-94 Reduced 0.69%
13,603 $80,000
Q2 2019

Aug 13, 2019

BUY
$9.44 - $13.12 $1,132 - $1,574
120 Added 0.88%
13,697 $164,000
Q1 2019

May 06, 2019

SELL
$12.07 - $17.54 $5,322 - $7,735
-441 Reduced 3.15%
13,577 $164,000
Q4 2018

Feb 13, 2019

SELL
$11.25 - $16.17 $1,226 - $1,762
-109 Reduced 0.77%
14,018 $176,000
Q3 2018

Nov 09, 2018

BUY
$12.82 - $17.88 $3,294 - $4,595
257 Added 1.85%
14,127 $210,000
Q2 2018

Aug 08, 2018

BUY
$16.83 - $21.66 $40,644 - $52,308
2,415 Added 21.08%
13,870 $233,000
Q1 2018

May 07, 2018

SELL
$19.24 - $28.03 $11,851 - $17,266
-616 Reduced 5.1%
11,455 $262,000
Q4 2017

Feb 09, 2018

BUY
$13.96 - $29.05 $795 - $1,655
57 Added 0.47%
12,071 $312,000
Q3 2017

Nov 09, 2017

BUY
$13.91 - $15.31 $167,114 - $183,934
12,014
12,014 $177,000

Others Institutions Holding CNCE

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0

About CONCERT PHARMACEUTICALS, INC.


  • Ticker CNCE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,934,600
  • Description
  • Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...
More about CNCE
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.